ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 96.52 Billion KRW | 235.08% |
| 2022 | 28.8 Billion KRW | -25.65% |
| 2021 | 38.74 Billion KRW | -8.67% |
| 2020 | 42.42 Billion KRW | 45.15% |
| 2019 | 29.22 Billion KRW | 113.3% |
| 2018 | 13.7 Billion KRW | 13.21% |
| 2017 | 12.1 Billion KRW | 76.87% |
| 2016 | 6.84 Billion KRW | 44.79% |
| 2015 | 4.72 Billion KRW | -32.89% |
| 2014 | 7.04 Billion KRW | 27.41% |
| 2013 | 5.52 Billion KRW | 39.59% |
| 2012 | 3.95 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 12.23 Billion KRW | -64.95% |
| 2024 Q1 | 34.9 Billion KRW | 56.15% |
| 2023 FY | 96.52 Billion KRW | 235.08% |
| 2023 Q3 | 21.3 Billion KRW | -49.92% |
| 2023 Q4 | 22.35 Billion KRW | 4.92% |
| 2023 Q2 | 42.53 Billion KRW | 311.48% |
| 2023 Q1 | 10.33 Billion KRW | -1.79% |
| 2022 FY | 28.8 Billion KRW | -25.65% |
| 2022 Q4 | 10.52 Billion KRW | 90.14% |
| 2022 Q3 | 5.53 Billion KRW | -2.74% |
| 2022 Q2 | 5.69 Billion KRW | -19.33% |
| 2022 Q1 | 7.05 Billion KRW | -57.17% |
| 2021 Q3 | 6.44 Billion KRW | 2.0% |
| 2021 Q4 | 16.47 Billion KRW | 155.53% |
| 2021 Q1 | 11.88 Billion KRW | 132.93% |
| 2021 FY | 38.74 Billion KRW | -8.67% |
| 2021 Q2 | 6.32 Billion KRW | -46.81% |
| 2020 Q2 | 13.43 Billion KRW | 36.05% |
| 2020 Q4 | 5.1 Billion KRW | -63.59% |
| 2020 Q3 | 14.01 Billion KRW | 4.28% |
| 2020 FY | 42.42 Billion KRW | 45.15% |
| 2020 Q1 | 9.87 Billion KRW | -32.41% |
| 2019 Q3 | 5.49 Billion KRW | 4.51% |
| 2019 Q1 | 3.86 Billion KRW | 13.85% |
| 2019 FY | 29.22 Billion KRW | 113.3% |
| 2019 Q4 | 14.61 Billion KRW | 165.82% |
| 2019 Q2 | 5.25 Billion KRW | 36.14% |
| 2018 FY | 13.7 Billion KRW | 13.21% |
| 2018 Q4 | 3.39 Billion KRW | 3.44% |
| 2018 Q3 | 3.28 Billion KRW | 11.71% |
| 2018 Q2 | 2.93 Billion KRW | -28.26% |
| 2018 Q1 | 4.09 Billion KRW | 47.84% |
| 2017 Q2 | 2.11 Billion KRW | -52.05% |
| 2017 FY | 12.1 Billion KRW | 76.87% |
| 2017 Q4 | 2.76 Billion KRW | -1.51% |
| 2017 Q1 | 4.4 Billion KRW | 77.84% |
| 2017 Q3 | 2.81 Billion KRW | 32.93% |
| 2016 Q2 | 1.11 Billion KRW | 62.95% |
| 2016 Q4 | 2.47 Billion KRW | -3.25% |
| 2016 FY | 6.84 Billion KRW | 44.79% |
| 2016 Q1 | 684.97 Million KRW | -60.27% |
| 2016 Q3 | 2.56 Billion KRW | 129.62% |
| 2015 Q2 | 537.11 Million KRW | -69.79% |
| 2015 Q1 | 1.77 Billion KRW | 12.35% |
| 2015 FY | 4.72 Billion KRW | -32.89% |
| 2015 Q4 | 1.72 Billion KRW | 150.81% |
| 2015 Q3 | 687.45 Million KRW | 27.99% |
| 2014 Q4 | 1.58 Billion KRW | -11.52% |
| 2014 FY | 7.04 Billion KRW | 27.41% |
| 2014 Q1 | 1.94 Billion KRW | 50.54% |
| 2014 Q2 | 1.72 Billion KRW | -11.35% |
| 2014 Q3 | 1.78 Billion KRW | 3.66% |
| 2013 FY | 5.52 Billion KRW | 39.59% |
| 2013 Q1 | 1.47 Billion KRW | 0.0% |
| 2013 Q2 | 1.47 Billion KRW | 0.0% |
| 2013 Q4 | 1.29 Billion KRW | 0.0% |
| 2013 Q3 | 1.29 Billion KRW | -12.1% |
| 2012 FY | 3.95 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -124.992% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -906.974% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 37.657% |
| Bioneer Corporation | 263.23 Billion KRW | 63.332% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -1384.911% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | -40.616% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -1878.471% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -2197.277% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 89.882% |
| Medy-Tox Inc. | 221.12 Billion KRW | 56.348% |
| Peptron, Inc. | 3.34 Billion KRW | -2788.271% |
| Amicogen, Inc. | 159.9 Billion KRW | 39.637% |
| Genexine, Inc. | 4.42 Billion KRW | -2080.507% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | -79.581% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -182.68% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 63.02% |
| SillaJen, Inc. | 3.93 Billion KRW | -2350.095% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | -64.389% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -465.643% |
| Genomictree Inc. | 3.41 Billion KRW | -2723.952% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -416.8% |
| EASY BIO,Inc. | 165.38 Billion KRW | 41.637% |
| GI Innovation, Inc. | 5.31 Billion KRW | -1714.733% |